Survodutide advances metabolic disease treatment, while biosimilar capacity expands, FDA delays hemophilia review, and lupus data support next steps.
|Articles|November 15, 2001
- BioPharm International-11-01-2001
- Volume 14
- Issue 11
Employing Murine MAbs as Ancillary Products in Cell Therapy Manufacturing, Part 2, A Case Study
Author(s)Steven Ford, William E. Tente
by Steven Ford and William E. Tente Chimeric Therapies, Inc. Experience shows that murine MAbs used in cell therapy manufacturing can be produced with safety concerns in mind. In such cases, adequate characterization ensures that they retain functional integrity.
Advertisement
Articles in this issue
almost 25 years ago
Business Matters: Eclipsed by Catastrophealmost 25 years ago
Designs for Bioassays with Plate Location Effectsalmost 25 years ago
Liposomes (a Review), Part One: Manufacturing Issuesalmost 25 years ago
Simplifying Pharmacologic Analysis with Programmable Scientific Softwarealmost 25 years ago
Outsourcing Outlook: Truth in OutsourcingAdvertisement
Related to this article
Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.
Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.
Doubled drug substance capacity at Alvotech's Reykjavik, Iceland, site aims to secure steady US supply of the Humira biosimilar Simlandi.
The glucagon/GLP-1 dual agonist hit both weight loss endpoints in phase 3, though gastrointestinal discontinuations and competitor data temper the readout.
CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
Advertisement
Advertisement